NCT04891302

The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19

A Double Blind, Randomized, Placebo-controlled, Multi-center, Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Mild and Moderate COVID-19

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 104 (actual)
• Sponsor: Bukwang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 150 mg versus placebo once daily administration with standard of care therapy for 10 days in patients with mild and moderate COVID-19.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Clevudine	Clevudine 150mg (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
DRUG	Placebo	Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days

Timeline

• Start date: 2021-03-19
• Primary completion: 2021-07-05
• Completion: 2021-07-08
• First posted: 2021-05-18
• Last updated: 2022-07-22

Locations

11 sites across 1 country: South Korea